A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Urology

• Publication date

  1998-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0090-4295(98)00173-3PMID 9697791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical trial of massive stilboestrol diphosphate therapy in advanced carcinoma of the prostate.

  2008cited by this paper
• Chemotherapy for advanced hormone refractory prostate cancer.

  1999cited by this paper
• Metastatic prostate cancer: assessment of response to systemic therapy.

  1997cited by this paper
• Secondary hormonal therapy.

  1997cited by this paper
• New agents in the therapy of hormone-refractory patients with prostate cancer.

  1995cited by this paper
• Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer

  1993cited by this paper
• Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/month.

  1990cited by this paper
• Combined hormonal therapy with high‐dose diethylstilbestrol diphosphate (DES‐DP) intravenous infusion plus vindesine (VND) for the treatment of advanced prostatic carcinoma: A controlled study

  1990cited by this paper
• Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group.

  1989cited by this paper
• Comparison of Megace, Stilphostrol, Megace plus DES, or streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy.

  1989cited by this paper
• Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.

  1989cited by this paper
• High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

  1989cited by this paper
• Effects of High‐Dose Ketoconazole in Patients with Androgen‐Independent Prostatic Cancer

  1988cited by this paper
• Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.

  1986cited by this paper
• A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

  1985cited by this paper
• A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.

  1985cited by this paper
• Hormonal Therapy of Prostatic Cancer

  1980cited by this paper
• Hormonal therapy of prostatic cancer.

  1980cited by this paper
• The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review.

  1975cited by this paper
• The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review.

  1975cited by this paper
• Paraplegia and paraparesis due to prostatic cancer. Use of intravenous diethylstilbestrol diphosphate.

  1974cited by this paper
• The veterans administration cooperative urological research group's studies of cancer of the prostate

  1973cited by this paper
• THE PLACE OF HONVAN (DIETHYLSTILB(ESTROL DIPHOSPHATE) IN THE TREATMENT OF PROSTATIC CANCER

  1965cited by this paper
• THE PLACE OF HONVAN (DIETHYLSTILBOESTROL DIPHOSPHATE) IN THE TREATMENT OF PROSTATIC CANCER; A REVIEW OF TWENTY-FOUR CASES.

  1965cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper

• Analysis of the Gene Networks and Pathways Correlated with Tissue Differentiation in Prostate Cancer

  2024cites this paper
• Impact of Human SULT1E1 Polymorphisms on the Sulfation of 17β-Estradiol, 4-Hydroxytamoxifen, and Diethylstilbestrol by SULT1E1 Allozymes

  2020cites this paper
• The use of Transdermal Oestrogen in Castrate- resistant, Steroid-refractory Prostate Cancer

  2020influential citation
• The resurgence of estrogens in the treatment of castration-resistant prostate cancer

  2019cites this paper
• Diethylstilbestrol in the Treatment of Castration-resistant Prostate Cancer: A Lower-middle-income Country Experience

  2019cites this paper
• Bioactive metabolites of Ganoderma lucidum: Factors, mechanism and broad spectrum therapeutic potential

  2019cites this paper
• The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer.

  2019cites this paper
• Rapid prolactin induction in adult male rats after treatment with diethylstilbestrol

  2019cites this paper
• Eficacia y seguridad del dietiletilbestrol, en el tratamiento del cáncer de próstata resistente a la castración

  2018cites this paper
• Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration‐resistant prostate cancer in men

  2018cites this paper
• The phytoestrogen genistein prevents trabecular bone loss and affects thyroid follicular cells in a male rat model of osteoporosis

  2018cites this paper
• A Study of Combination Bicalutamide and Raloxifene for Patients With Castration‐Resistant Prostate Cancer

  2017cites this paper
• Elucidation of the Molecular Mechanisms Underlying Estrogen-Mediated Estrogen Receptor Activation

  2017cites this paper
• Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.

  2017cites this paper
• Prostate cancer: improving outcomes in Australia through rapid access diagnostics

  2016cites this paper
• Implementing newer agents for the management of castrate‐resistant prostate cancer: what is known and what is needed?

  2015cites this paper
• The Hormonal Management of Metastatic Prostate Cancer

  2015cites this paper
• Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.

  2014influential citation
• Diethylstilboestrol for the treatment of prostate cancer: past, present and future

  2014cites this paper
• DETERMINATION OF DIETHYLSTILBESTROL IN HUMAN PLASMA WITH MEASUREMENT UNCERTAINTY ESTIMATION BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY

  2014cites this paper
• Diethylstilboestrol (1 mg) in the Management of Castration-Resistant Prostate Cancer

  2014cites this paper
• Metastatic Prostate Cancer: Chemohormonal Therapy Extends Survival by More than a Year

  2014cites this paper
• Development and Preclinical PK / PD Evaluations of Diethylstilbestrol Nanosuspensions in Rats

  2013cites this paper
• DIETHYLSTILBESTROL: A TRAGEDY IN REPRODUCTIVE ENDOCRINOLOGY BUT A PIONEERING CANCER TREATMENT

  2013cites this paper
• Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'

  2013cites this paper
• Quantitative proteomic determination of diethylstilbestrol action on prostate cancer.

  2013cites this paper
• Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response

  2013cites this paper
• Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.

  2013cites this paper
• Guidelines on Prostate Cancer

  2013cites this paper
• The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy.

  2013cites this paper
• Characterization of endocrine disruptors from a complex matrix using estrogen receptor affinity columns and high performance liquid chromatography–high resolution mass spectrometry

  2013cites this paper
• MODULATION OF SEXUAL AND SLEEP FUNCTIONS BY ESTROGEN IN CASTRATED MALE RATS AS A MODEL FOR PROSTATE CANCER PATIENTS ON ANDROGEN DEPRIVATION THERAPY

  2013cites this paper
• Tratamiento con dietilestilbestrol en pacientes refractarios a la castracion por analogos LH- RH Treatment with diethylstilbestrol in patients who had failed to androgen deprivation by lhrh agonists

  2013cites this paper
• Early vs. Delayed Hormonal Treatment in Locally Advanced orAsymptomatic Metastatic Prostatic Cancer Patient Dilemma: A Review

  2013cites this paper
• Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer

  2013influential citation
• Estrogens in the time of blood-thinners.

  2013cites this paper
• Radium-223 for the treatment of prostate cancer

  2013cites this paper
• Characterization of UDP-glucuronosyltransferases involved in glucuronidation of diethylstilbestrol in human liver and intestine.

  2012cites this paper
• New developments in castrate‐resistant prostate cancer

  2012cites this paper
• Optimal Management of Recurrent Prostate Cancer in Older Patients

  2012cites this paper
• Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?

  2012cites this paper
• Prostate‐specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration‐resistant prostate cancer

  2012cites this paper
• Castration‐resistant prostate cancer: Many treatments, many options, many challenges ahead

  2012cites this paper
• Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment

  2012cites this paper
• Current role of diethylstilbestrol in the management of advanced prostate cancer

  2012cites this paper
• Current management of castration- resistant prostate cancer (CRPC)

  2012cites this paper
• Molecular progression of prostate cancer: Androgens and estrogens

  2012cites this paper
• Diethylstilbestrol in castration‐resistant prostate cancer

  2012cites this paper
• MDV3100 for the treatment of prostate cancer

  2012cites this paper
• Effect of Estrogen Administration on The Prostate of the Adult Albino Rat ( Histological , Ultrastructural and Immunohistological Studies )

  2011cites this paper
• Kastrationsresistentes Prostatakarzinom 2011

  2011cites this paper
• Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.

  2011cites this paper
• Current Treatment Strategies for Castration-Resistant Prostate Cancer

  2011cites this paper
• Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol.

  2011cites this paper
• Stratégies thérapeutiques du cancer de la prostate résistant à la castration Strategies in castration-resistant prostate cancer

  2011cites this paper
• [Strategies in castration-resistant prostate cancer].

  2011cites this paper
• Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer

  2010cites this paper
• Guía clínica sobre el cáncer de próstata

  2010cites this paper
• Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration‐resistant prostate cancer

  2010cites this paper
• CHAPTER 86 – The Prostate

  2010cites this paper
• Рак предстательной железы

  2010cites this paper
• Modification and implementation of NCCN guidelines on prostate cancer in the Middle East and North Africa region.

  2010cites this paper
• Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cites this paper
• Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cites this paper
• Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region.

  2010cites this paper
• Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer

  2010influential citation
• Perkembangan triwulanan perekonomian Indonesia

  2009cites this paper
• Optimization of cisplatin for the treatment of hormone-dependent tumoral diseases: Part 2: Use of non-steroidal ligands

  2009cites this paper
• Ganoderma lucidum: a potent pharmacological macrofungus.

  2009cites this paper
• Clinical Progression to Castration-Recurrent Prostate Cancer

  2009cites this paper
• 5α‐Reductase Isozymes and Androgen Actions in the Prostate

  2009cites this paper
• Highlighting Unmet Needs: Real Patients, Difficult Choices

  2009cites this paper
• Etude du ligand TRAIL et ses récepteurs dans la prostate normale et pathologique reliée au statut hormonal

  2008cites this paper
• Secondary hormonal manipulation.

  2008cites this paper
• Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancer

  2008cites this paper
• Prediction of survival in prostate cancer aspects on localised, locally advanced and metastatic disease

  2008cites this paper
• Treating asymptomatic patients with hormone‐refractory prostate cancer: hormonal manipulations for the urologist

  2008cites this paper
• [Management of metastatic androgeno-independent prostate cancer].

  2008cites this paper
• Development of drugs against hormone‐refractory prostate cancer

  2008cites this paper
• Diethylstilbestrol and docetaxel

  2007cites this paper
• Rising Prostate-Specific Antigen after Primary Treatment of Prostate Cancer: Sequential Hormone Manipulation

  2007cites this paper
• Clinical and Biological Activity of Soy Protein Powder Supplementation in Healthy Male Volunteers

  2007cites this paper
• Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies

  2007cites this paper
• Treatment options for hormone-refractory prostate cancer.

  2007cites this paper
• Rising PSA in nonmetastatic prostate cancer.

  2007cites this paper
• Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.

  2007cites this paper
• Estrogens and aspects of prostate disease

  2007cites this paper
• Expression of Nkx3.1 enhances 17beta-estradiol anti-tumor action in PC3 human prostate cancer cells.

  2007cites this paper
• [Prostatic cancers].

  2007cites this paper
• Cancer de la prostate

  2007cites this paper
• UROLOGICAL ONCOLOGY: PROSTATE CANCER

  2007cites this paper
• Secondary hormonal therapy for advanced prostate cancer.

  2006cites this paper
• Secondary hormonal manipulations in prostate cancer.

  2006cites this paper
• Secondary hormonal manipulations in prostate cancer

  2006cites this paper
• Advancing prostate cancer: treatment options for the urologist.

  2006cites this paper
• Management of prostate cancer. Part 3: metastatic disease

  2006cites this paper
• [Hormone-refractory prostate cancer. Modifications of the therapeutic strategies since chemotherapy proved its usefulness].

  2006cites this paper
• The case for secondary hormonal therapies in the chemotherapy age.

  2006cites this paper
• Cáncer de próstata hormonorresistente: Cambios en las estrategias terapéuticas desde la demostración de la utilidad de la quimioterapia

  2006cites this paper
• Management Strategies for Hormone-Refractory Prostate Cancer

  2006cites this paper